Abstract: tamoxifen citrate, as the first line of treatment for infertile men with idiopathic oligozoospermia, was proposed by the World Health Organization (WHO), and testosterone undecanoate has shown benefits in semen values. Our objective was to assess the effectiveness of treatment with tamoxifen citrate and testosterone undecanoate in infertile men with idiopathic oligozoospermia, and whether the results would be affected by polymorphisms of CYP2D6*10. A total of 230 infertile men and 147 controls were included in the study. Patients were treated with tamoxifen citrate and testosterone undecanoate. Sex hormone, sperm parameters, and incidence of spontaneous pregnancy were detected. There were no significant differences between the control and patient groups with respect to CYP2D6*10 genotype frequencies (P>0.05). The follicle-stimulation hormone (FSH), luteinizing hormone (LH), and testosterone (T) levels were raised, and sperm concentration and motility were increased at 3 months and became significant at 6 months, and they were higher in the wild-type allele (C/C) than in the heterozygous variant allele (C/T) or homozygous variant allele (T/T) subgroups (P<0.05). In addition, the percentage of normal morphology was raised at 6 months, and represented the highest percentage in the C/C subgroup (P<0.05). The incidence of spontaneous pregnancy in the C/C subgroup was higher than that in the C/T or T/T subgroups (P<0.01). This study showed that the CYP2D6*10 variant genotype demonstrated worse clinical effects in infertile men with idiopathic oligozoospermia.

CYP2D6*10基因多态性对他莫昔芬联合十一酸睾酮治疗特发性少精男性不育症的疗效影响

[1]Adamopoulos, D.A., Nicopoulou, S., Kapolla, N., et al., 1997. The combination of testosterone undecanoate with tamoxifen citrate enhances the effects of each agent given independently on seminal parameters in men with idiopathic oligozoospermia. Fertil. Steril., 67(4):756-762.

[2]Adamopoulos, D.A., Pappa, A., Billa, E., et al., 2003. Effectiveness of combined tamoxifen citrate and testosterone undecanoate treatment in men with idiopathic oligozoospermia. Fertil. Steril., 80(4):914-920.

[3]Borges, S., Desta, Z., Li, L., et al., 2006. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin. Pharmacol. Ther., 80(1):61-74.

[4]Buvat, J., Ardaens, K., Lemaire, A., et al., 1983. Increased sperm count in 25 cases of idiopathic normogonadotropic oligospermia following treatment with tamoxifen. Fertil. Steril., 39(5):700-703.

[5]Chua, M.E., Escusa, K.G., Luna, S., et al., 2013. Revisiting oestrogen antagonists (clomiphene or tamoxifen) as medical empiric therapy for idiopathic male infertility: a meta-analysis. Andrology, 1(5):749-757.

[6]Comhaire, F., 1976. Treatment of oligospermia with tamoxifen. Int. J. Fertil., 21(4):232-238.

[7]Desta, Z., Ward, B.A., Soukhova, N.V., et al., 2004. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther., 310(3):1062-1075.

[8]Garcia-Barcelo, M., Chow, L.Y., Chiu, H.F., et al., 2000. Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population. Clin. Chem., 46(1):18-23.

[9]Ji, L., Pan, S.X., Wu, J.M., et al., 2002a. Genetic polymorphisms of CYP2D6 in Chinese mainland. Chin. Med. J., 115(12):1780-1784.

[10]Ji, L., Pan, S.X., Marti-Jaun, J., et al., 2002b. Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in mainland Chinese. Clin. Chem., 48(7):983-988.

[11]Jin, Y., Desta, Z., Stearns, V., et al., 2005. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl. Cancer Inst., 97(1):30-39.

[12]Johansson, I., Oscarson, M., Yue, Q.Y., et al., 1994. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol., 46(3):452-459.

[13]Kadioglu, T.C., Koksal, I.T., Tunc, M., et al., 1999. Treatment of idiopathic and postvaricocelectomy oligozoospermia with oral tamoxifen citrate. BJU Int., 83(6):646-648.

[14]Kotoulas, I.G., Cardamakis, E., Michopoulos, J., et al., 1994. Tamoxifen treatment in male infertility. I. Effect on spermatozoa. Fertil. Steril., 61(5):911-914.

[15]Lin, C.H., Lien, H.C., Hu, F.C., et al., 2010. Fractionated evaluation of immunohistochemical hormone receptor expression enhances prognostic prediction in breast cancer patients treated with tamoxifen as adjuvant therapy. J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.), 11(1):1-9.

[16]Lu, W.J., Desta, Z., Flockhart, D.A., 2012. Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer. Breast Cancer Res. Treat., 131(2):473-481.

[17]Rowe, P.J., Comhaire, F.H., Hargreave, T.B., et al., 2000. WHO Manual for the Standardized Investigation, Diagnosis and Management of the Infertile Male. Cambridge University Press, London, England, p.432-441.

[18]Sachse, C., Brockmoller, J., Bauer, S., et al., 1997. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet., 60(2):284-295.

[19]Squirewell, E.J., Qin, X., Duffel, M.W., 2014. Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab. Dispos., 42(11):1843-1850.

[20]Stearns, V., Johnson, M.D., Rae, J.M., et al., 2003. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl. Cancer Inst., 95(23):1758-1764.

[21]Vermeulen, A., Comhaire, F., 1978. Hormonal effects of an antiestrogen, tamoxifen, in normal and oligospermic men. Fertil. Steril., 29(3):320-327.

[22]WHO (World Health Organization), 1999. WHO Laboratory Manual for the Examination of Human Semen and Sperm-Cervical Mucus Interactions, 4th Ed. Cambridge University Press, London, England, p.270-278.

[23]Xu, Y., Sun, Y., Yao, L., et al., 2008. Association between CYP2D6*10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann. Oncol., 19(8):1423-1429.